<?xml version="1.0" encoding="UTF-8" standalone="yes"?><dealRecordsOutput><serviceExecutionTime>255</serviceExecutionTime><Deal id="107026"><Title>BioGeneriX to codevelop Neose's GlycoPEG-GCSF worldwide excluding US, Canada, Mexico, and Japan  </Title><CompanyPrincipal id="24203">Neose Technologies Inc</CompanyPrincipal><CompanyPartner id="1007757">BioGeneriX AG</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="Payment Unspecified" max="0.0" min="0.0"/><ValueProjected accuracy="&gt;" max="79.0" min="79.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><TerritoriesIncluded><Territory id="WO">World</Territory></TerritoriesIncluded><TerritoriesExcluded><Territory id="CA">Canada</Territory><Territory id="JP">Japan</Territory><Territory id="MX">Mexico</Territory><Territory id="US">US</Territory></TerritoriesExcluded><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1646155</Reference><Type>Other Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="3.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1835943</Reference><Type>Sales Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="34.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1835943</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="26.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Other Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="3.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1835943</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2004 Q4">15.0</ReportedAmountMil></Value></Payment><Payment><Reference>1835943</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="2.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1835943</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="0.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1835943</Reference><Type>Option Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2004 Q1">10.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="3.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="3.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2004 Q1">10.0</ReportedAmountMil></Value></Payment><Payment><Reference>582252</Reference><Type>R&amp;D Funding</Type><Value accuracy="Payment Unspecified"/></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="1991">Neutropenia</Indication></Indications><ActionsPrimary><Action id="3151">GCSF receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="610">Hematopoietic stimulator</Action></ActionsSecondary><Technologies><Technology id="348">PEGylated formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="589">Sustained release formulation</Technology></Technologies><DateStart>2004-04-20T00:00:00Z</DateStart><DateEnd>2009-01-27T00:00:00Z</DateEnd><DateEventMostRecent>2009-01-27T00:00:00Z</DateEventMostRecent><Drugs><Drug id="43497"><DrugNameDisplay>GlycoPEGylated erythropoietin, Neose</DrugNameDisplay><PhaseHighestStart id="PC">Preclinical</PhaseHighestStart><PhaseHighestNow id="DX">Discontinued</PhaseHighestNow></Drug><Drug id="51128"><DrugNameDisplay>lipegfilgrastim (neutropenia), BioGeneriX</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In April 2004, &lt;ulink linkType="Company" linkID="24203"&gt;Neose Technologies&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="1007757"&gt;BioGeneriX&lt;/ulink&gt; signed an agreement to use Neose's GlycoPEGylation technology to develop a &lt;ulink linkType="Drug" linkID="51128"&gt;long-acting, next-generation granulocyte colony stimulating factor&lt;/ulink&gt; (GCSF; GlycoPED-GCSF).  BioGeneriX was to have worldwide commercial rights, excluding the US, Canada, Mexico, and Japan [&lt;ulink linkType="Reference" linkID="533922"&gt;533922&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1833309"&gt;1833309&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1835791"&gt;1835791&lt;/ulink&gt;]. In January 2005, Neose Technologies and BioGeneriX  entered into a supply and option agreement for the use of Neose's GlycoPEGylation technology to develop a long-acting, next-generation version of an existing protein  [&lt;ulink linkType="Reference" linkID="582252"&gt;582252&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1833665"&gt;1833665&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1835943"&gt;1835943&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1836137"&gt;1836137&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1836469"&gt;1836469&lt;/ulink&gt;].  In October 2006, an amendment was made to this agreement, whereby Neose would have the right to end the agreement immediately if Biogenerix did not begin a phase I trial by November 16, 2006 [&lt;ulink linkType="Reference" linkID="734004"&gt;734004&lt;/ulink&gt;]. In January 2007, BioGeneriX decided to continue development of the drug. However, at that time,  BioGeneriX declined to take up an option to develop Neose's &lt;ulink linkType="Drug" linkID="43497"&gt;GlycoPEGylated erythropoietin&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="754560"&gt;754560&lt;/ulink&gt;]. In September 2008, it was announced that Neose planned to liquidate and divest all of its assets to &lt;ulink linkType="Company" linkID="18614"&gt;Novo Nordisk&lt;/ulink&gt;, and BioGeneriX [&lt;ulink linkType="Reference" linkID="944421"&gt;944421&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="944455"&gt;944455&lt;/ulink&gt;]. However, in January 2009, Neose entered liquidation and divested all its assets to Novo Nordisk and BioGeneriX [&lt;ulink linkType="Reference" linkID="979528"&gt;979528&lt;/ulink&gt;].   &lt;/para&gt;</Summary><TimeLine><Event><Date>2006-12-31T00:00:00Z</Date><Drugs><DrugLink id="43497" nameDisplay="GlycoPEGylated erythropoietin, Neose"/></Drugs><Summary>&lt;para&gt;- In December 2006, BioGeneriX declined to exercise its option to an exclusive, worldwide license to Neose's GlycoPEGylation technology for use with a GlycoPEGylated erythropoietin made in Chinese hamster ovary (CHO) cells (GlycoPEG-CHO-EPO).&lt;/para&gt;&lt;para&gt;- The parties announced plans to  continue the GlycoPEG-GCSF collaboration (upon expirtion of the termination option).&lt;/para&gt;&lt;para&gt;- BioGeneriX would continue with clinical development, subject to the additional phase I and II diligence requirements added under the October 2006 amendment.&lt;/para&gt;&lt;para&gt;- BioGenerix would assume Neose's cost of reagent supply for clinical development as of January 1, 2007.&lt;/para&gt;&lt;para&gt;- The product was in phase I in Western Europe at this time [&lt;ulink linkType="Reference" linkID="1646155"&gt;1646155&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2004-04-20T00:00:00Z</Date><Drugs><DrugLink id="51128" nameDisplay="lipegfilgrastim (neutropenia), BioGeneriX"/></Drugs><PaymentsToPrincipal><Payment><Reference id="533922">533922</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="2">Payment Unspecified</Accuracy></Value></Payment></PaymentsToPrincipal><Stage id="PC">Preclinical</Stage><StageNotes>&lt;para&gt;lipegfilgrastim is in preclinical.&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- In April 2004, &lt;ulink linkType="Company" linkID="24203"&gt;Neose Technologies&lt;/ulink&gt; signed an agreement with &lt;ulink linkType="Company" linkID="1007757"&gt;BioGeneriX&lt;/ulink&gt; AG (a ratiopharm subsidiary) to use Neose's GlycoPEGylation technology to develop a &lt;ulink linkType="Drug" linkID="51128"&gt;long-acting, next-generation version of granulocyte colony stimulating factor&lt;/ulink&gt; (GCSF). &lt;/para&gt;&lt;para&gt;- GCSF is a protein used to promote the production of neutrophils in patients underoging ablative chemotherapy. &lt;/para&gt;&lt;para&gt;- Neose's GlycoPEGylation technology extends the half life of protein products by linking polyethylene glycol (PEG) polymers to glycans that are remote from the protein's active site, thereby preserving activity. &lt;/para&gt;&lt;para&gt;- BioGenerix would pay $1M upfront, up to $3M in its share of co-development expenses, and $3.5M on U.S. product launch. &lt;/para&gt;&lt;para&gt;- The parties would share preclinical expenses, and BioGeneriX will fund the entire clinical development program. &lt;/para&gt;&lt;para&gt;- Neose would retain commercial rights in North America and Japan. &lt;/para&gt;&lt;para&gt;- BioGeneriX would have commercial rights in Europe and rest of world. &lt;/para&gt;&lt;para&gt;- Each company would receive royalties on product sales in the other company's territory: &lt;/para&gt;&lt;para&gt;- BioGeneriX would pay 7% of annual sales up to $150M and 10% of annual net sales above $150M. &lt;/para&gt;&lt;para&gt;- Neose would pay 17% of annual sales up to $150M and 20% of annual net sales above $150M. &lt;/para&gt;&lt;para&gt;- BioGeneriX AG was founded in June 2000 to develop biosimilars. It is a subsidiary of ratiopharm, a large European generics company and former member of the Merckle group. Ratiopharm was acquired in 2010 by Teva pharmaceuticals [&lt;ulink linkType="Reference" linkID="533922"&gt;533922&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1833309"&gt;1833309&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1835791"&gt;1835791&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2005-01-28T00:00:00Z</Date><Drugs><DrugLink id="43497" nameDisplay="GlycoPEGylated erythropoietin, Neose"/><DrugLink id="51128" nameDisplay="lipegfilgrastim (neutropenia), BioGeneriX"/></Drugs><PaymentsToPrincipal><Payment><Reference id="582252">582252</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="2">Payment Unspecified</Accuracy></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;In January 2005, Neose Technologies and BioGeneriX  entered into a supply and option agreement for the use of Neose's GlycoPEGylation technology to develop a long-acting, next-generation version of an existing protein. The companies would enter into an initial 3-month research period, during which Neose would receive payment and a supply of protein for research purposes. During this period, BioGenerix may choose to enter into a research, license and option agreement. In return Neose would receive additional upfront research and milestone payments of up to $61.5 million, as well as royalties. BioGeneriX had an option for an exclusive, worldwide license to use Neose's GlycoPEGylation technology to develop and commercialize a long-acting, next generation version of the protein. See Financial Notes for further financial details   [&lt;ulink linkType="Reference" linkID="582252"&gt;582252&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1833665"&gt;1833665&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1835943"&gt;1835943&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1836137"&gt;1836137&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1836469"&gt;1836469&lt;/ulink&gt;].  &lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2005-04-27T00:00:00Z</Date><Drugs><DrugLink id="43497" nameDisplay="GlycoPEGylated erythropoietin, Neose"/><DrugLink id="51128" nameDisplay="lipegfilgrastim (neutropenia), BioGeneriX"/></Drugs><PaymentsToPrincipal><Payment><Reference id="598335">598335</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="2">Payment Unspecified</Accuracy></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;In April 2005, the research, license and option agreement was granted to BioGeneriX as a result of the exercise of option  by BioGeneriX. &lt;/para&gt;&lt;para&gt;- Option expiration date on the ninetieth day after the end of the Research Term. &lt;/para&gt;&lt;para&gt;- Neose grants to BioGeneriX  exclusive right and option to obtain an exclusive license under the Neose Technology to develop and commercialize the Product. &lt;/para&gt;&lt;para&gt;- BioGeneriX might exercise the option by providing written notice of exercise to Neose at any time on or before the option expiration date. &lt;/para&gt;&lt;para&gt;- Upfront fee, $500,000, payable upon the execution of the agreement, of which $200,000 has been paid pursuant to the supply and option agreement dated as of January 28, 2005, and (ii) $300,000, would be paid simultaneously with the execution  in connection with the exercise of the option pursuant to supply and option agreement&lt;/para&gt;&lt;para&gt;-   BioGeneriX would pay royalties to Neose on net sales of the product in the territory in each calendar year during the term of the agreement, as follows:&lt;/para&gt;&lt;para&gt;-  7% of the portion of net sales of the product in the calendar year up to $200,000,000;  11% of the portion of net sales of the product in the calendar year greater than $200,000,000 and up to $600,000,000. &lt;/para&gt;&lt;para&gt;- 15% of the portion of net sales of the product in the calendar year greater than $600,000,000. &lt;/para&gt;&lt;para&gt;- BioGeneriX would pay milestone payments in the amounts upon the occurrence of the respective milestone event: &lt;/para&gt;&lt;para&gt;- $1,500,000 upon the exercise of the option. $1,000,000 upon the first administration of the next generation CHO-EPO in humans. &lt;/para&gt;&lt;para&gt;- $1,000,000 upon the accrual of the first subject in a phase IIIclinical trial of next generation CHO-EPO. &lt;/para&gt;&lt;para&gt;- $2,000,000 upon the first filing for regulatory approval for the product with the EMEA or other regulatory authority in the EU.&lt;/para&gt;&lt;para&gt;-  $4,000,000 upon the first launch of the product in any country in the EU.&lt;/para&gt;&lt;para&gt;- $4,000,000 when cumulative net sales of the product in the EU first exceed $2,000,000.&lt;/para&gt;&lt;para&gt;- $3,000,000 upon launch of the product in Japan. &lt;/para&gt;&lt;para&gt;- $5,000,000 upon the first filing for the regulatory approval with the FDA in the US. &lt;/para&gt;&lt;para&gt;- $10,000,000 upon launch of the product in the US. &lt;/para&gt;&lt;para&gt;- $10,000,000 when cumulative net sales of the product in the US first exceed $50,000,000.&lt;/para&gt;&lt;para&gt;-  $5,000,000 when net sales in the territory first exceed $100,000,000 in any calendar year and $15,000,000 when net sales in the territory first exceed $500,000,000 in any calendar year [&lt;ulink linkType="Reference" linkID="598335"&gt;598335&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1833665"&gt;1833665&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Option Exercised</Type></Event><Event><Date>2006-09-22T00:00:00Z</Date><Drugs><DrugLink id="51128" nameDisplay="lipegfilgrastim (neutropenia), BioGeneriX"/></Drugs><Summary>&lt;para&gt;In September 2006, BioGeneriX announced that it might delay the start of phase I trials unless it could find a partner to finance the studies. If BioGeneriX didn't start a trial in accordance with the agreement, worldwide rights to the the GlycoPEG-GCSF program would revert to Neose by mid-February 2007 [&lt;ulink linkType="Reference" linkID="693111"&gt;693111&lt;/ulink&gt;]. In October 2006, an amendment was made to this agreement, whereby Neose would have the right to end the agreement immediately if Biogenerix did not begin a phase I trial by November 16, 2006 [&lt;ulink linkType="Reference" linkID="734004"&gt;734004&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event><Event><Date>2007-01-01T00:00:00Z</Date><Drugs><DrugLink id="43497" nameDisplay="GlycoPEGylated erythropoietin, Neose"/><DrugLink id="51128" nameDisplay="lipegfilgrastim (neutropenia), BioGeneriX"/></Drugs><Summary>&lt;para&gt;In January 2007, BioGeneriX decided to continue development of the drug. However, at that time,  BioGeneriX declined to take up an option to develop Neose's &lt;ulink linkType="Drug" linkID="43497"&gt;GlycoPEGylated erythropoietin&lt;/ulink&gt;. No financial terms were disclosed [&lt;ulink linkType="Reference" linkID="754560"&gt;754560&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Option Declined</Type></Event><Event><Date>2008-09-19T00:00:00Z</Date><Drugs><DrugLink id="51128" nameDisplay="lipegfilgrastim (neutropenia), BioGeneriX"/></Drugs><Summary>&lt;para&gt;In September 2008, it was announced that Neose planned to liquidate and divest all of its assets to &lt;ulink linkType="Company" linkID="18614"&gt;Novo Nordisk&lt;/ulink&gt;, and BioGeneriX, for a total consideration of $43 million; divestment to Novo Nordisk was valued at $21 million. This decision was still subject to shareholder approval at the time (see separate September 2008 deal).&lt;/para&gt;&lt;para&gt;- BioGenerix purchased the full rights to Neose&amp;amp;apos;s GlycoPEG technology for use with the GCSF product for about $22M, within the context of Neose liquidation (see separate transaction).&lt;/para&gt;&lt;para&gt;- The product was then in phase II development  [&lt;ulink linkType="Reference" linkID="944421"&gt;944421&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="944455"&gt;944455&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2009-01-27T00:00:00Z</Date><Drugs><DrugLink id="51128" nameDisplay="lipegfilgrastim (neutropenia), BioGeneriX"/></Drugs><Stage id="C2">Phase 2 Clinical</Stage><StageNotes>&lt;para&gt;lipegfilgrastim is in phase II.&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;In January 2009, Neose entered liquidation and divested all its assets to Novo Nordisk and BioGeneriX. No financial terms were disclosed [&lt;ulink linkType="Reference" linkID="979528"&gt;979528&lt;/ulink&gt;]. FOIA version/replaced&lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event></TimeLine><Patents><Patent id="IN1488754"><Number>US-05032519</Number><Title>Method For Producing Secretable Glycosyltransferases And Other Golgi Processing Enzymes</Title></Patent></Patents><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="43497" type="Drug"><TargetEntity id="366654" type="siDrug">GlycoPEG-EPO</TargetEntity></SourceEntity><SourceEntity id="24203" type="Company"><TargetEntity id="4295907363" type="organizationId">Neose Technologies Inc</TargetEntity></SourceEntity><SourceEntity id="1007757" type="Company"><TargetEntity id="5035524934" type="organizationId">BiogeneriX AG</TargetEntity></SourceEntity><SourceEntity id="1991" type="ciIndication"><TargetEntity id="D70" type="ICD10"/><TargetEntity id="10029354" type="MEDDRA"/><TargetEntity id="D009503" type="MeSH"/><TargetEntity id="-506284464" type="omicsDisease"/><TargetEntity id="1002" type="siCondition"/></SourceEntity><SourceEntity id="3151" type="Action"><TargetEntity id="3384" type="Mechanism">G-CSF Receptor Agonists</TargetEntity><TargetEntity id="1121" type="Mechanism">G-CSF Mimetics</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="115718"><Title>Eli Lilly and Elan to form worldwide Alzheimer's disease alliance  </Title><CompanyPrincipal id="17810">Eli Lilly &amp; Co</CompanyPrincipal><CompanyPartner id="26414">Elan Pharmaceuticals Inc</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="6.3" min="6.3"/><ValueProjected accuracy="=" max="12.6" min="12.6"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="=" max="55.0" min="55.0"/></ValuesToPartner><TerritoriesIncluded><Territory id="WO">World</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPartner><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="27.5" usdExchangeRate="1.0" usdExchangeRatePeriod="1988 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="27.5" usdExchangeRate="1.0" usdExchangeRatePeriod="1988 Q3">0.0</ReportedAmountMil></Value></Payment></PaymentsToPartner><PaymentsToPrincipal><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1988 Q3">10.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="0.3" usdExchangeRate="1.0" usdExchangeRatePeriod="1988 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="0.3" usdExchangeRate="1.0" usdExchangeRatePeriod="1988 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1988 Q3">10.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Contingent Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="4.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1988 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="2.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1988 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Contingent Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="4.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1988 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="2.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1988 Q3">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="14">Alzheimers disease</Indication></Indications><ActionsPrimary><Action id="2421">Beta amyloid synthesis inhibitor</Action><Action id="7578">Gamma-secretase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1615">Neuroprotectant</Action><Action id="284">Nootropic agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="111">Cloning technology</Technology><Technology id="585">Oral formulation</Technology></Technologies><DateStart>1988-12-31T00:00:00Z</DateStart><DateEnd>1998-08-25T00:00:00Z</DateEnd><DateEventMostRecent>1998-08-25T00:00:00Z</DateEventMostRecent><Drugs><Drug id="12016"><DrugNameDisplay>A-beta-I-196</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="NDR">No Development Reported</PhaseHighestNow></Drug><Drug id="10899"><DrugNameDisplay>cytokine release modulator, Lilly</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DX">Discontinued</PhaseHighestNow></Drug><Drug id="29417"><DrugNameDisplay>semagacestat</DrugNameDisplay><PhaseHighestStart id="C2">Phase 2 Clinical</PhaseHighestStart><PhaseHighestNow id="DX">Discontinued</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In 1988,  &lt;ulink linkType="Company" linkID="17810"&gt;Eli Lilly&lt;/ulink&gt; and Athena Neurosciences (now  &lt;ulink linkType="Company" linkID="26414"&gt;Elan Pharmaceuticals&lt;/ulink&gt;)  established a research collaboration to discover and develop potential treatment for Alzheimer's disease (AD), including &lt;ulink linkType="Drug" linkID="29417"&gt;semagacestat&lt;/ulink&gt; (LY-450139)  [&lt;ulink linkType="Reference" linkID="551918"&gt;551918&lt;/ulink&gt;]. In June 1995, the companies signed a joint licensing agreement for a transgenic mouse model for AD; amending the original agreement&lt;ulink linkType="Drug" linkID="10899"&gt;&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="178695"&gt;178695&lt;/ulink&gt;]. In February 1997,  the alliance was extended through to August 1998. By that time the two companies were also investigating  &lt;ulink linkType="Drug" linkID="12016"&gt;A-beta-I-196&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="234381"&gt;234381&lt;/ulink&gt;]. The collaboration ended by August 1998  [&lt;ulink linkType="Reference" linkID="556198"&gt;556198&lt;/ulink&gt;].   &lt;/para&gt;</Summary><TimeLine><Event><Date>1988-12-31T00:00:00Z</Date><Drugs><DrugLink id="29417" nameDisplay="semagacestat"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1646155">1646155</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="1988 Q3" exchangeRateUS="1">0.3</USDAmountMil></Value></Payment><Payment><Reference id="1646155">1646155</Reference><Type>Upfront Equity</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="1988 Q3" exchangeRateUS="1">6</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="C2">Phase 2 Clinical</Stage><Summary>&lt;para&gt;In 1988,  &lt;ulink linkType="Company" linkID="17810"&gt;Eli Lilly and Co&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="26414"&gt;Elan Pharmaceuticals Inc&lt;/ulink&gt;  established a research collaboration to discover and develop potential treatment for Alzheimer's disease. By April 2004, &lt;ulink linkType="Drug" linkID="29417"&gt;semagacestat&lt;/ulink&gt; (LY-450139) had entered phase II trials for Alzheimer's disease [&lt;ulink linkType="Reference" linkID="551918"&gt;551918&lt;/ulink&gt;]. &lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>1998-08-25T00:00:00Z</Date><Drugs/><Summary>&lt;para&gt;The collaboration ended by August  1998 with Lilly being granted an exclusive, worldwide license under certain patents to make, have made, use and sell any compound owned by Elan and discovered during the exclusive collaboration. Elan retained certain commercial rights under the collaboration agreement [&lt;ulink linkType="Reference" linkID="556198"&gt;556198&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event><Event><Date>1997-08-20T00:00:00Z</Date><Drugs><DrugLink id="12016" nameDisplay="A-beta-I-196"/></Drugs><Summary>&lt;para&gt;In February 1997, Elan and Lilly agreed to extend the alliance through to August 1998. By that time the two companies were also investigating  &lt;ulink linkType="Drug" linkID="12016"&gt;A-beta-I-196&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="234381"&gt;234381&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>1995-06-01T00:00:00Z</Date><Drugs><DrugLink id="10899" nameDisplay="cytokine release modulator, Lilly"/></Drugs><Summary>&lt;para&gt;In June 1995, Athena  and Eli Lilly signed a joint licensing agreement for a transgenic mouse model for Alzheimer's disease.  They amended their original 1998 Alzheimer's collaboration, reinforcing that each company had equal rights to the mouse model.  Lilly would increase its funding to support Athena's research efforts.The model was used to develop a series of &lt;ulink linkType="Drug" linkID="10899"&gt;cytokine release modulators&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="178695"&gt;178695&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event></TimeLine><Patents><Patent id="PA3133687"><Number>US-06610493</Number><Title>Screening compounds for the ability to alter the production of amyloid-beta peptide</Title></Patent></Patents><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="29417" type="Drug"><TargetEntity id="322926" type="siDrug">Semagacestat</TargetEntity></SourceEntity><SourceEntity id="26414" type="Company"><TargetEntity id="4296931209" type="organizationId">Elan Pharmaceuticals LLC</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"/><TargetEntity id="331.0" type="ICD9"/><TargetEntity id="10012271" type="MEDDRA"/><TargetEntity id="D000544" type="MeSH"/><TargetEntity id="-1268969445" type="omicsDisease"/><TargetEntity id="101" type="siCondition"/></SourceEntity><SourceEntity id="2421" type="Action"><TargetEntity id="3617" type="Mechanism">beta-Amyloid (Abeta) Production Inhibitors</TargetEntity></SourceEntity><SourceEntity id="7578" type="Action"><TargetEntity id="1368" type="Mechanism">gamma-Secretase Inhibitors</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="123229"><Title>Baxter to develop and commercialize Cantab's Anti-CD45, LM-CD45 for transplant rejection in ex-Asia  </Title><CompanyPrincipal id="15303">Cantab Biopharmaceuticals Ltd</CompanyPrincipal><CompanyPartner id="14437">Baxter International Inc</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="6.2" min="6.2"/><ValueProjected accuracy="=" max="13.3" min="13.3"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><TerritoriesIncluded><Territory id="X0">Africa</Territory><Territory id="AU">Australia</Territory><Territory id="CA">Canada</Territory><Territory id="X5">Europe</Territory><Territory id="MX">Mexico</Territory><Territory id="XJ">Middle East</Territory><Territory id="NZ">New Zealand</Territory><Territory id="XE">South America</Territory><Territory id="US">US</Territory></TerritoriesIncluded><TerritoriesExcluded><Territory id="X2">Asia</Territory></TerritoriesExcluded><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1991 Q2">17.5</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="6.2" usdExchangeRate="1.0" usdExchangeRatePeriod="1991 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1.2" usdExchangeRate="1.0" usdExchangeRatePeriod="1991 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="5.9" usdExchangeRate="1.0" usdExchangeRatePeriod="1991 Q2">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="515">Transplant rejection</Indication></Indications><ActionsPrimary><Action id="5171">CD45 antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="396">Immunosuppressant</Action></ActionsSecondary><Technologies><Technology id="51">Monoclonal antibody</Technology></Technologies><DateStart>1991-08-23T00:00:00Z</DateStart><DateEnd>1995-05-09T00:00:00Z</DateEnd><DateEventMostRecent>1995-05-09T00:00:00Z</DateEventMostRecent><Drugs><Drug id="7396"><DrugNameDisplay>LM-CD45</DrugNameDisplay><PhaseHighestStart id="C2">Phase 2 Clinical</PhaseHighestStart><PhaseHighestNow id="DX">Discontinued</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In August1991, &lt;ulink linkType="Company" linkID="14437"&gt;Baxter&lt;/ulink&gt;   agreed to develop and commercialize  &lt;ulink linkType="Company" linkID="15303"&gt;Cantab&lt;/ulink&gt;'s Anti-CD45, &lt;ulink linkType="Drug" linkID="7396"&gt;LM-CD45&lt;/ulink&gt; for transplant rejection in ex-Asia [&lt;ulink linkType="Reference" linkID="159685"&gt;159685&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1854643"&gt;1854643&lt;/ulink&gt;]. However, in May 1995,  Cantab has announced the discontinuation of the program and it was assumed that the deal was terminated [&lt;ulink linkType="Reference" linkID="177055"&gt;177055&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>1995-05-09T00:00:00Z</Date><Drugs><DrugLink id="7396" nameDisplay="LM-CD45"/></Drugs><Summary>&lt;para&gt;- In May 1995,  Cantab has announced the discontinuation of the program following poor clinical trial results and it was assumed that the deal was terminated [&lt;ulink linkType="Reference" linkID="177055"&gt;177055&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event><Event><Date>1994-08-23T00:00:00Z</Date><Drugs><DrugLink id="7396" nameDisplay="LM-CD45"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1646155">1646155</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="1994 Q2" exchangeRateUS="1">6.2</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="DR">Discovery</Stage><Summary>&lt;para&gt;- In August1991, &lt;ulink linkType="Company" linkID="14437"&gt;Baxter&lt;/ulink&gt;   agreed to develop and commercialize  &lt;ulink linkType="Company" linkID="15303"&gt;Cantab&lt;/ulink&gt;'s Anti-CD45, &lt;ulink linkType="Drug" linkID="7396"&gt;LM-CD45&lt;/ulink&gt; for transplant rejection in ex-Asia.&lt;/para&gt;&lt;para&gt;-  Upfront of $6.2 million, R&amp;amp;D funding of $1.2 million, development and regulatory milestones of $5.9 million, 17.5% royalty  [&lt;ulink linkType="Reference" linkID="159685"&gt;159685&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1854643"&gt;1854643&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><Patents><Patent id="IN883998"><Number>US-04350683</Number><Title>Antibody Production From Hybrid Cell Line</Title></Patent></Patents><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="7396" type="Drug"><TargetEntity id="201322" type="siDrug">LM-CD45</TargetEntity></SourceEntity><SourceEntity id="14437" type="Company"><TargetEntity id="4295903531" type="organizationId">Baxter International Inc</TargetEntity></SourceEntity><SourceEntity id="15303" type="Company"><TargetEntity id="5035523582" type="organizationId">Cantab Biopharmaceuticals Ltd</TargetEntity></SourceEntity><SourceEntity id="515" type="ciIndication"><TargetEntity id="10044439" type="MEDDRA"/><TargetEntity id="D006084" type="MeSH"/><TargetEntity id="1133" type="siCondition"/></SourceEntity><SourceEntity id="5171" type="Action"><TargetEntity id="1595" type="Mechanism">Anti-CD45</TargetEntity><TargetEntity id="3446" type="Mechanism">Protein Tyrosine Phosphatase PTP CD45 Inhibitors</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="123713"><Title>Fujisawa Healthcare to develop Discovery Therapeutics' injectible selodenoson in North America</Title><CompanyPrincipal id="22342">Aderis Pharmaceuticals Inc</CompanyPrincipal><CompanyPartner id="25526">Fujisawa Healthcare Inc</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="Payment Unspecified" max="0.0" min="0.0"/><ValueProjected accuracy="&gt;" max="26.0" min="26.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><TerritoriesIncluded><Territory id="CA">Canada</Territory><Territory id="US">US</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1646155</Reference><Type>Lump Sum</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="13.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1999 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Lump Sum</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="13.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1999 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="Payment Unspecified"/></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="1542">Atrial fibrillation</Indication><Indication id="57">Cardiovascular disease</Indication><Indication id="27">Heart arrhythmia</Indication></Indications><ActionsPrimary><Action id="20">Adenosine A1 receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="449">Antiarrhythmic agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="628">Formulation other</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><DateStart>1999-08-02T00:00:00Z</DateStart><DateEnd>2004-07-30T00:00:00Z</DateEnd><DateEventMostRecent>2004-07-30T00:00:00Z</DateEventMostRecent><Drugs><Drug id="19500"><DrugNameDisplay>selodenoson (injectable), Aderis</DrugNameDisplay><PhaseHighestStart id="C1">Phase 1 Clinical</PhaseHighestStart><PhaseHighestNow id="DX">Discontinued</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In August 1999, &lt;ulink linkType="Company" linkID="25526"&gt;Fujisawa Healthcare&lt;/ulink&gt; was granted exclusive North American development and marketing rights to &lt;ulink linkType="Company" linkID="22342"&gt;Discovery Therapeutics&lt;/ulink&gt;' (now Aderis Pharmaceuticals) &lt;ulink linkType="Drug" linkID="19500"&gt;DTI-0009&lt;/ulink&gt; (injectible selodenoson) [&lt;ulink linkType="Reference" linkID="334844"&gt;334844&lt;/ulink&gt;]; however, Fujisawa terminated its involvement  in July 2004  [&lt;ulink linkType="Reference" linkID="553123"&gt;553123&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>1999-07-29T00:00:00Z</Date><Drugs><DrugLink id="19500" nameDisplay="selodenoson (injectable), Aderis"/></Drugs><PaymentsToPrincipal><Payment><Reference id="334844">334844</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="2">Payment Unspecified</Accuracy></Value></Payment></PaymentsToPrincipal><Stage id="C1">Phase 1 Clinical</Stage><Summary>&lt;para&gt;In August 1999, &lt;ulink linkType="Company" linkID="25526"&gt;Fujisawa Healthcare&lt;/ulink&gt; was granted exclusive North American development and marketing rights to &lt;ulink linkType="Company" linkID="22342"&gt;Discovery Therapeutics&lt;/ulink&gt;' (now Aderis Pharmaceuticals) &lt;ulink linkType="Drug" linkID="19500"&gt;DTI-0009&lt;/ulink&gt; (injectible selodenoson). Financial details were undisclosed [&lt;ulink linkType="Reference" linkID="334844"&gt;334844&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2004-07-30T00:00:00Z</Date><Drugs><DrugLink id="19500" nameDisplay="selodenoson (injectable), Aderis"/></Drugs><Summary>&lt;para&gt;In July 2004, Fujisawa terminated its involvement    [&lt;ulink linkType="Reference" linkID="553123"&gt;553123&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event></TimeLine><Patents><Patent id="IN2157000"><Number>US-05310731</Number><Title>N-6 Substituted-5'-(N-Substitutedcarboxamido)Adenosines As Cardiac Vasodilators And Antihypertensive Agents</Title></Patent></Patents><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="19500" type="Drug"><TargetEntity id="280140" type="siDrug">Selodenoson</TargetEntity></SourceEntity><SourceEntity id="25526" type="Company"><TargetEntity id="4296621340" type="organizationId">Fujisawa Healthcare Inc</TargetEntity></SourceEntity><SourceEntity id="22342" type="Company"><TargetEntity id="4296402556" type="organizationId">Aderis Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1542" type="ciIndication"><TargetEntity id="10003658" type="MEDDRA"/><TargetEntity id="D001281" type="MeSH"/><TargetEntity id="-1073626038" type="omicsDisease"/><TargetEntity id="194" type="siCondition"/></SourceEntity><SourceEntity id="27" type="ciIndication"><TargetEntity id="10003119" type="MEDDRA"/><TargetEntity id="D001145" type="MeSH"/><TargetEntity id="-100431042" type="omicsDisease"/><TargetEntity id="189" type="siCondition"/></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"/><TargetEntity id="D002318" type="MeSH"/><TargetEntity id="-1500764314" type="omicsDisease"/><TargetEntity id="182" type="siCondition"/></SourceEntity><SourceEntity id="20" type="Action"><TargetEntity id="28" type="Mechanism">Adenosine A1 Agonists</TargetEntity></SourceEntity></CrossReferences></Deal></dealRecordsOutput>